Drugs / 23-PPV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02545868 | Oct 2015 → Feb 2017 | relapsing-remitting multiple sclerosis | Hoffmann-La Roche | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 23-PPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02545868 ↗ |
| Known as | Pneumovax | “All received tetanus toxoid (TT)-containing vaccine, Pneumovax (23-valent pneumococcal polysaccharide vaccine [23-PPV]), and keyhole limpet hemocyanin (KLH).” PMID 32727835 ↗ Jul 2020 |
| Modality | Vaccine | “The 23-PPV vaccine will be given as a 0.5-milliliter (mL) intramuscular (IM) injection in the deltoid muscle on Day 112 (Group A) or Day 28 (Group B).” NCT02545868 ↗ |
| Route | Intramuscular | “intramuscular (IM) injection” NCT02545868 ↗ |